Assess whether the primary endpoint will survive FDA scrutiny (24174d)

SITUATION CMC and Development Pathways work in a 505(b)(2) program relying on literature plus a bridging study now turns on the primary endpoint will because a literature paper the 505(b)(2) package leans on getting retracted put CMC comparability package for a site change in play. Labeling negotiator should say what CMC comparability package for a site change proves.

DECISION Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after a literature paper the 505(b)(2) package leans on getting retracted.

HYPOTHESES TO TEST 1. A literature paper the 505(b)(2) package leans on getting retracted is noise around an already-controlled CMC and Development Pathways process in a 505(b)(2) program relying on literature plus a bridging study, given CMC comparability package for a site change. 2. A literature paper the 505(b)(2) package leans on getting retracted is the event in CMC comparability package for a site change that forces Proceed under protocol for labeling negotiator under Pharma & Life Sciences. 3. CMC comparability package for a site change shows a one-file miss after a literature paper the 505(b)(2) package leans on getting retracted, not a CMC and Development Pathways program failure. 4. CMC comparability package for a site change cannot decide the primary endpoint will yet after a literature paper the 505(b)(2) package leans on getting retracted; hold is the only Pharma & Life Sciences close a 505(b)(2) program relying on literature plus a bridging study can defend.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in CMC comparability package for a site change after a literature paper the 505(b)(2) package leans on getting retracted. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read CMC comparability package for a site change against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move the primary endpoint will for labeling negotiator.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (CMC comparability package for a site change after a literature paper the 505(b)(2) package leans on getting retracted). Lead with the Pharma & Life Sciences option CMC comparability package for a site change can support after a literature paper the 505(b)(2) package leans on getting retracted, then the two facts that force it, then the Monday action for labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study.